Galectin-1 and -9 in angiogenesis: A sweet couple

Glycobiology

Volumn 24, Issue 10, 2014, Pages 915-920

  Lthijssen, Victor ^a   Griffioen, Arjan W ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Angiogenesis; Endothelial cell; Galectin; Splicing

Indexed keywords

ECALECTIN; GALECTIN 1; GALECTIN; LGALS1 PROTEIN, HUMAN; LGALS9 PROTEIN, HUMAN;

ANGIOGENESIS; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CYTOLOGY; ENDOTHELIUM CELL; IN VITRO STUDY; PRIORITY JOURNAL; REVIEW; CARCINOGENESIS; GENETICS; HUMAN; METABOLISM; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION;

CARCINOGENESIS; ENDOTHELIAL CELLS; GALECTIN 1; GALECTINS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84911880716     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwu048     Document Type: Review

References (56)

1. Ahmad N, Gabius HJ, Sabesan S, Oscarson S, Brewer CF. 2004. Thermodynamic binding studies of bivalent oligosaccharides to galectin-1, galectin-3, and the carbohydrate recognition domain of galectin-3. Glycobiology. 14:817-825.
2. Alam S, Li H, Margariti A, Martin D, Zampetaki A, Habi O, Cockerill G, Hu Y, Xu Q, Zeng L. 2011. Galectin-9 protein expression in endothelial cells is positively regulated by histone deacetylase 3. J Biol Chem. 286:44211-44217.
3. Amano M, Galvan M, He J, Baum LG. 2003. The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J Biol Chem. 278:7469-7475.
4. Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, et al. 2002. Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol. 169:5912-5918.
5. Balan V, Nangia-Makker P, Kho DH, Wang Y, Raz A. 2012. Tyrosine-phosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage. J Biol Chem. 287:5192-5198.
6. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, et al. 1994. Galectins: A family of animal beta-galactoside-binding lectins. Cell. 76:597-598.
7. Baum LG, Seilhamer JJ, Pang M, Levine WB, Beynon D, Berliner JA. 1995. Synthesis of an endogeneous lectin, galectin-1, by human endothelial cells is up-regulated by endothelial cell activation. Glycoconj J. 12:63-68.
8. Belanis L, Plowman SJ, Rotblat B, Hancock JF, Kloog Y. 2008. Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters. Mol Biol Cell. 19:1404-1414.
9. Camby I, Le Mercier M, Lefranc F, Kiss R. 2006. Galectin-1: A small protein with major functions. Glycobiology. 16:137R-157R.
10. Cardenas Delgado VM, Nugnes LG, Colombo LL, Troncoso MF, Fernandez MM, Malchiodi EL, Frahm I, Croci DO, Compagno D, Rabinovich GA, et al. 2011. Modulation of endothelial cell migration and angiogenesis: A novel function for the "tandem-repeat" lectin galectin-8. FASEBJ. 25:242-254.
11. Chabot S, Kashio Y, Seki M, Shirato Y, Nakamura K, Nishi N, Nakamura T, Matsumoto R, Hirashima M. 2002. Regulation of galectin-9 expression and release in Jurkat Tcell line cells. Glycobiology. 12:111-118.
12. Clausse N, van den Brule F, Waltregny D, Garnier F, Castronovo V 1999. Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis. 3:317-325.
13. Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, et al. 2014. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 156:744-758.
14. Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, Ouyang J, Ilarregui JM, Toscano MA, Domaica CI, et al. 2012. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med. 209:1985-2000.
15. D'Haene N, Sauvage S, Maris C, Adanja I, Le Mercier M, Decaestecker C, Baum L, Salmon I. 2013. VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis. PLoS ONE. 8:e67029.
16. Earl LA, Bi S, Baum LG. 2011. Galectin multimerization and lattice formation are regulated by linker region structure. Glycobiology. 21:6-12.
17. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y 2002. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem. 277:37169-37175.
18. Freitag N, Tirado-González I, Barrientos G, Herse F, Thijssen VL, Weedon-Fekjær SM, Schulz H, Wallukat G, Klapp BF, Nevers T, et al. 2013. Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia. Proc Natl Acad Sci USA. 110:11451-11456.
19. Gabius HJ, Brehler R, Schauer A, Cramer F. 1986. Localization of endogenous lectins in normal human breast, benign breast lesions and mammary carcinomas. Virchows Arch B Cell Pathol Incl MolPathol. 52:107-115.
20. Griffioen AW, Molema G 2000. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 52:237-268.
21. Heusschen R, Griffioen AW, Thijssen VL. 2013. Galectin-9 in tumor biology: A jack of multiple trades. Biochim Biophys Acta. 1836:177-185.
22. Heusschen R, Schulkens IA, van Beijnum J, Griffioen AW, Thijssen VL. 2014. Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochim Biophys Acta. 1842:284-292.
23. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, Futai M, Muller WE, et al. 2002. Oligosaccharide specificity of galectins: A search by frontal affinity chromatography. Biochim Biophys Acta. 1572:232-254.
24. Hsieh SH, Ying NW, Wu MH, Chiang WF, Hsu CL, Wong TY, Jin YT, Hong TM, Chen YL. 2008. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene. 27:3746-3753.
25. Imaizumi T, Kumagai M, Sasaki N, Kurotaki H, Mori F, Seki M, Nishi N, Fujimoto K, Tanji K, Shibata T, et al. 2002. Interferon-{gamma} stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol. 72:486-491.
26. Ito K, Scott SA, Cutler S, Dong LF, Neuzil J, Blanchard H, Ralph SJ. 2011. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis. 14:293-307.
27. Jouve N, Despoix N, Espeli M, Gauthier L, Cypowyj S, Fallague K, Schiff C, Dignat-George F, Vély F, Leroyer AS. 2013. The involvement of CD146 and its novel ligand Galectin-1 in apoptotic regulation of endothelial cells. J Biol Chem. 288:2571-2579.
28. La M, Cao TV, Cerchiaro G, Chilton K, Hirabayashi J, Kasai K, Oliani SM, Chernajovsky Y, Perretti M. 2003. A novel biological activity for galectin-1: Inhibition of leukocyte-endothelial cell interactions in experimental inflammation. Am JPathol. 163:1505-1515.
29. Leal-Pinto E, Tao W, Rappaport J, Richardson M, Knorr BA, Abramson RG 1997. Molecular cloning and functional reconstitution of a urate transporter/channel. J Biol Chem. 272:617-625.
30. Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F. 2004. Introduction to galectins. Glycoconj J. 19:433-440.
31. Le Mercier M, Mathieu V, Haibe-Kains B, Bontempi G, Mijatovic T, Decaestecker C, Kiss R, Lefranc F. 2008. Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol. 67:456-469.
32. Leppänen A, Stowell S, Blixt O, Cummings RD. 2005. Dimeric galectin-1 binds with high affinity to alpha2, 3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface-bound extended glycans. J Biol Chem. 280:5549-5562.
33. Lipkowitz MS, Leal-Pinto E, Cohen BE, Abramson RG. 2004. Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconj J. 19:491-498.
34. Makishi S, Okudaira T, Ishikawa C, Sawada S, Watanabe T, Hirashima M, Sunakawa H, Mori N. 2008. A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells. Br J Haematol. 142:583-594.
35. Mathieu V, de Lassalle EM, Toelen J, Mohr T, Bellahcène A, Van Goietsenoven G, Verschuere T, Bouzin C, Debyser Z, De Vleeschouwer S, et al. 2012. Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol. 132:2245-2254.
36. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL, Hirashima M. 1998. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem. 273:16976-16984.
37. Mazurek N, Conklin J, Byrd JC, Raz A, Bresalier RS. 2000. Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands. J Biol Chem. 275:36311-36315.
38. Miura T, Takahashi M, Horie H, Kurushima H, Tsuchimoto D, Sakumi K, Nakabeppu Y. 2004. Galectin-1beta, a natural monomeric form of galectin-1 lacking its six amino-terminal residues promotes axonal regeneration but not cell death. Cell Death Differ. 11:1076-1083.
39. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. 2000. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 156:899-909.
40. Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, Raz A. 2010. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer. 127:2530-2541.
41. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, Shoji H, Nakamura T. 2005. Development of highly stable galectins: Truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett. 579:2058-2064.
42. Nishi N, Itoh A, Shoji H, Miyanaka H, Nakamura T. 2006. Galectin-8 and galectin-9 are novel substrates for thrombin. Glycobiology. 16:15C-20C.
43. Nishioka T, Sakumi K, Miura T, Tahara K, Horie H, Kadoya T, Nakabeppu Y. 2002. FosB gene products trigger cell proliferation and morphological alteration with an increased expression of a novel processed form of galectin-1 in the rat 3Y1 embryo cell line. J Biochem (Tokyo). 131:653-661.
44. Rabinovich GA, Croci DO. 2012. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity. 6:322-335.
45. Sanjuan X, Fernandez PL, Castells A, Castronovo V, van den Brule F, Liu FT, Cardesa A, Campo E. 1997. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology. 113:1906-1915.
46. Saussez S, Decaestecker C, Cludts S, Ernoux P, Chevalier D, Smetana KJ, Andre S, Leroy X, Gabius HJ. 2009. Adhesion/growth-regulatory tissue lectin galectin-1 in relation to angiogenesis/lymphocyte infiltration and prognostic relevance of stromal up-regulation in laryngeal carcinomas. Anticancer Res. 29:59-65.
47. Schulkens IA, Griffioen AW, Thijssen VL. 2012. Angiostatic cancer therapy by targeting galectins in the tumor vasculature. In: Klyosov A, editor. ACS Symposium Series: Galectins and Disease Implications for Targeted Therapeutics. Washington (DC): ACS Publications.
48. Spitzenberger F, Graessler J, Schroeder HE. 2001. Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. Biochimie. 83:851-862.
49. Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, Hackeng TM, Kiss R, Kloog Y, Poirier F, et al. 2010. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 70:6216-6224.
50. Thijssen VL, Hulsmans S, Griffioen AW. 2008. The galectin profile of the endothelium: Altered expression and localization in activated and tumor endothelial cells. Am J Pathol. 172:545-553.
51. Thijssen VL, Rabinovich GA, Griffioen AW. 2013. Vascular galectins: Regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev. 24:547-558.
52. Thijssen VL, Poirier F, Baum LG, Griffioen AW. 2007. Galectins in the tumor endothelium; opportunities for combined cancer therapy. Blood. 110:2819-2827.
53. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, et al. 2006. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA. 103:15975-15980.
54. Tureci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U. 1997. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J Biol Chem. 272:6416-6422.
55. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS. 1997. Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J Clin Invest. 99:2452-2461.
56. Wu H, Chen P, Liao R, Li YW, Yi Y, Wang JX, Sun TW, Zhou J, Shi YH, Yang XR, et al. 2012. Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection. J Gastroenterol Hepatol. 27:1312-1319.